Zevin Asset Management LLC Reduces Stock Holdings in GlaxoSmithKline plc (NYSE:GSK)

Zevin Asset Management LLC reduced its holdings in GlaxoSmithKline plc (NYSE:GSK) by 16.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,701 shares of the pharmaceutical company’s stock after selling 4,340 shares during the period. Zevin Asset Management LLC’s holdings in GlaxoSmithKline were worth $969,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Prestige Wealth Management Group LLC purchased a new stake in shares of GlaxoSmithKline during the 2nd quarter worth about $26,000. Berman Capital Advisors LLC boosted its stake in GlaxoSmithKline by 58.1% in the 2nd quarter. Berman Capital Advisors LLC now owns 656 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares in the last quarter. Financial Gravity Wealth Inc. boosted its stake in GlaxoSmithKline by 62.7% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 799 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 308 shares in the last quarter. Manchester Financial Inc. acquired a new stake in GlaxoSmithKline in the 2nd quarter valued at $39,000. Finally, Ellis Investment Partners LLC boosted its stake in GlaxoSmithKline by 144.5% in the 3rd quarter. Ellis Investment Partners LLC now owns 1,022 shares of the pharmaceutical company’s stock valued at $43,000 after buying an additional 604 shares in the last quarter. 11.19% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have recently weighed in on the company. New Street Research upgraded GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research report on Wednesday, October 16th. Citigroup reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Wednesday. Cantor Fitzgerald upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating in a report on Friday, October 11th. ValuEngine upgraded GlaxoSmithKline from a “sell” rating to a “hold” rating in a report on Monday, October 21st. Finally, Goldman Sachs Group restated a “buy” rating on shares of GlaxoSmithKline in a research note on Wednesday, October 30th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the company. GlaxoSmithKline presently has a consensus rating of “Hold” and a consensus target price of $41.79.

In other news, Director Plc Glaxosmithkline purchased 177,777 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were purchased at an average price of $45.00 per share, with a total value of $7,999,965.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.00% of the company’s stock.

Shares of NYSE:GSK traded up $0.21 during mid-day trading on Friday, reaching $44.42. The company had a trading volume of 1,985,586 shares, compared to its average volume of 2,550,711. The company has a current ratio of 0.82, a quick ratio of 0.56 and a debt-to-equity ratio of 1.38. The firm has a market cap of $110.42 billion, a price-to-earnings ratio of 14.06, a PEG ratio of 3.03 and a beta of 0.70. The company’s 50-day moving average price is $42.96 and its 200-day moving average price is $41.12. GlaxoSmithKline plc has a one year low of $36.41 and a one year high of $46.01.

GlaxoSmithKline (NYSE:GSK) last issued its earnings results on Wednesday, October 30th. The pharmaceutical company reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.10. GlaxoSmithKline had a net margin of 13.76% and a return on equity of 92.73%. The business had revenue of $11.57 billion for the quarter, compared to analysts’ expectations of $11.34 billion. On average, research analysts anticipate that GlaxoSmithKline plc will post 3.08 EPS for the current fiscal year.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Story: How to find the components of the quick ratio

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.